Intermittent Fasting and Cancer: What the Research Says

Quick Answer: Early research suggests intermittent fasting may reduce cancer risk through multiple mechanisms — lower insulin, reduced inflammation, and enhanced cellular repair. Fasting during chemotherapy is an emerging area with promising early results but requires oncologist supervision. No fasting protocol should replace conventional cancer treatment.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Cancer treatment decisions must be made in consultation with a qualified oncologist. Do not alter your treatment plan or diet based on this article alone.

What We Know (and Don't Know) About Fasting and Cancer

Cancer research is complex, and fasting research is relatively young. What we have is a growing body of preclinical evidence (cell and animal studies), some observational data in humans, and a small number of clinical trials.

The honest summary: the mechanistic case for fasting reducing cancer risk is strong. The clinical evidence in humans is still developing. This distinction matters enormously when translating research into personal decisions.

Biological Mechanisms: Why Fasting May Matter for Cancer

Several biological pathways connect fasting to cancer biology:

Insulin and IGF-1 reduction The National Cancer Institute reports that people with obesity often carry higher blood levels of insulin and insulin-like growth factor 1 (IGF-1), and that high levels are associated with increased risk of colorectal, thyroid, breast, prostate, ovarian and endometrial cancers. Fasting lowers both. In a 2015 Cell Metabolism trial, 19 people who completed three monthly five-day cycles of a low-calorie fasting-mimicking diet — not a water fast — saw circulating IGF-1 fall about 24% by the end of the diet period, and stay about 15% below baseline after normal eating resumed (Brandhorst et al., 2015). Lower IGF-1 means less signaling through pathways that promote cell proliferation.

Autophagy Autophagy — the cellular "self-cleaning" process activated by fasting — allows the body to break down damaged and dysfunctional cells, including potentially pre-cancerous ones. The Nobel Prize in Physiology or Medicine was awarded in 2016 to Yoshinori Ohsumi for discoveries related to autophagy. While autophagy's role in cancer is dual-edged (it may suppress tumor initiation but also support survival in established tumors), its activation is generally considered protective in healthy cells.

Inflammation reduction Chronic inflammation is a well-established driver of cancer development, and the National Cancer Institute names it as one mechanism linking obesity to cancer. A 2025 network meta-analysis of 21 trials and 839 adults found that intermittent fasting produced small but statistically significant reductions in C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-α). It found no significant effect on interleukin-6 (IL-6). You can read more about how fasting affects metabolism and inflammatory signaling.

Blood glucose stabilization Cancer cells preferentially consume glucose — a concept known as the Warburg effect. By reducing blood glucose and insulin, fasting theoretically reduces the fuel available to rapidly dividing cells. This is an active area of research, and the degree to which dietary glucose restriction affects human tumors remains under study.

Fasting and Cancer Prevention: What the Evidence Shows

The National Cancer Institute links overweight and obesity to 13 types of cancer, among them postmenopausal breast, colorectal, endometrial and kidney cancer. Any intervention that reduces body fat and insulin resistance may therefore reduce cancer risk indirectly.

A 2016 study in JAMA Oncology followed 2,413 women with early-stage breast cancer for about seven years. Those who fasted fewer than 13 hours per night had a 36% higher risk of recurrence than those who fasted 13 or more hours (hazard ratio 1.36). The same study found no significant association with breast cancer mortality or death from any cause (Marinac et al., 2016). It was observational, so it cannot show that the fasting itself did the work.

The preclinical case is much stronger than the human one. As the 2018 Nature Reviews Cancer review puts it, animal data on fasting and cancer is robust while the clinical trials are still running. Whether rodent results translate to humans remains uncertain.

Fasting During Chemotherapy: An Emerging Field

This is perhaps the most clinically relevant — and most controversial — area of fasting and cancer research.

The concept is called differential stress resistance (DSR). The idea: fasting may make normal healthy cells more resistant to the toxic effects of chemotherapy, while cancer cells (which are biologically compelled to keep growing) cannot enter a protected low-energy state. In theory, this could reduce chemo side effects while potentially making cancer cells more vulnerable.

A dose-escalation pilot trial published in BMC Cancer (Dorff et al., 2016) put 20 patients through fasts of 24, 48 or 72 hours around platinum-based chemotherapy. It concluded that fasting for up to 72 hours was safe and feasible, with fasting-related side effects no worse than grade 2 — mostly fatigue, headache and dizziness. It reported a trend toward less severe neutropenia in the longer-fasting groups, but that trend was not statistically significant.

The larger DIRECT trial randomized 131 women with HER2-negative stage II/III breast cancer to a fasting-mimicking diet or a normal diet around neoadjuvant chemotherapy. Radiological response was more common in the fasting-mimicking arm, and there was no difference in toxicity between the groups (de Groot et al., 2020).

Crucially, this work was pioneered by Dr. Valter Longo at USC. However, fasting during chemotherapy is not a standard of care and should only be attempted under direct oncologist supervision. Some cancers and some chemotherapy regimens may not be appropriate candidates.

Who Should Be Cautious

Fasting is not appropriate for everyone with cancer:

• Anyone currently underweight or with poor nutritional status — the National Cancer Institute reports malnutrition in 30% to 85% of cancer patients, and notes that it increases treatment toxicity and accounts for 10% to 20% of deaths; fasting can worsen it
• People with cachexia (cancer-related muscle wasting) should not fast
• Those on certain medications where food timing matters
• People undergoing active treatment who have not discussed fasting with their oncologist

For cancer survivors in remission who are otherwise healthy, intermittent fasting may be appropriate as part of a broader metabolic health strategy — but again, only with physician involvement.

What About Specific Cancer Types?

Research is uneven across cancer types:

• Breast cancer: The most studied, and the only type with a randomized chemotherapy trial. Fat tissue produces estrogen, so losing body fat lowers it.
• Colorectal cancer: Strong mechanistic links through insulin resistance and inflammation. Less direct clinical data.
• Prostate cancer: The National Cancer Institute lists high insulin and IGF-1 among the risk factors; fasting lowers IGF-1. No major clinical trials yet.
• Brain tumors (glioblastoma): A handful of phase 1 and pilot trials of ketogenic diets, some combined with fasting. Feasibility and safety, not efficacy. Highly experimental.

Practical Recommendations

For cancer prevention:

• A consistent 16:8 fasting window combined with a whole-food diet and regular exercise is a reasonable metabolic health strategy
• Prioritize weight management — adipose tissue is metabolically active and pro-inflammatory
• Support insulin sensitivity through fasting and diet (see our guide on insulin and fasting)
• Avoid ultra-processed foods and excess sugar during your eating window

For cancer survivors:

• Discuss any fasting protocol with your oncology team before starting
• Start conservatively — 12–14 hours overnight is a reasonable entry point
• Focus on nutritional density during your eating window; do not use fasting as a justification for caloric restriction if you're underweight or recovering

For those in active treatment:

• Do not fast without direct oncologist approval
• If your oncologist is open to exploring fasting around chemotherapy, ask about clinical trial options

Frequently Asked Questions

Does intermittent fasting cure cancer?

No. There is no evidence that fasting cures cancer. It may reduce certain risk factors and, in conjunction with treatment, may have supportive effects — but it is not a cancer treatment. Anyone claiming fasting cures cancer is making an unsupported claim.

Can fasting feed cancer cells?

This concern is sometimes raised, but there is no evidence that short-term fasting "feeds" cancer cells. The Warburg effect describes cancer cells' preferential use of glucose, and fasting reduces blood glucose — the opposite of what this concern implies.

Is fasting safe during radiation therapy?

There is very limited research on fasting during radiation. Some preclinical data suggests potential benefit, but this has not been established in human trials. Speak with your radiation oncologist before making any dietary changes during treatment.

How long should I fast for potential cancer-protective effects?

Nobody knows. The Marinac study found an association between 13 or more hours of overnight fasting and lower breast cancer recurrence, but an association in an observational study is not a dose. IGF-1 reduction has only been measured after multi-day, low-calorie regimens. Everything in between is untested, so start conservatively — a beginners guide can help.

Citations

1. Brandhorst S, et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. Cell Metab. 2015;22(1):86–99.
2. Marinac CR, et al. Prolonged nightly fasting and breast cancer prognosis. JAMA Oncol. 2016;2(8):1049–1055.
3. Dorff TB, et al. Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 2016;16:360.
4. de Groot S, et al. Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nat Commun. 2020;11:3083.
5. Nencioni A, et al. Fasting and cancer: molecular mechanisms and clinical application. Nat Rev Cancer. 2018;18(11):707–719.
6. Khalafi M, et al. The effects of intermittent fasting on inflammatory markers in adults: a systematic review and pairwise and network meta-analyses. Nutrients. 2025;17(15):2388.
7. National Cancer Institute. Obesity and Cancer Fact Sheet; Nutrition in Cancer Care (PDQ) — Health Professional Version.